Custom Lucite celebrating the first-in-human trial of SOR 102, a treatment for nflammatory bowel disease. The drug was developed by Utah-based Sorriso Pharmaceuticals. (23AKL435)
Whether you’re celebrating a funding round, research collaboration, FDA-approval, or commemorating a deal in the biotech space, you’ll find inspiration in the custom designs below.
Custom Lucite celebrating the first-in-human trial of SOR 102, a treatment for nflammatory bowel disease. The drug was developed by Utah-based Sorriso Pharmaceuticals. (23AKL435)
Crystal financial tombstone celebrating Series B financing for Nuvig Therapeutics. The immune drug developer is based in Menlo Park, California. (24ALJ345)
Laboratory-themed crystal financial tombstone commemorating a capital raise by Sartorius Stedim Biotech. The biopharmaceutical company is based in Aubagne, France. (SO24LJW040)
Crystal tombstone commemorting a private placement and a follow-on offering by Calidi Biotherapeutics. The San Diego-based company specializes in the development of cell-based therapies. (24AKL339)
Custom Lucite deal toy marking the acquisition of two royalty interest in sales of breast cancer drug Orserdu. (24AKL125)
Crystal commemorative celebrating FDA approval of Ogsiveo, a treatment for desmoid tumors. (24aZH051)
Code name-themed crystal financial tombstone commemorating a partnership between Bayer and Pairwise. The joint venture will center on gene-editing capabilities for five crops: corn, soybean, wheat, cotton, and canola. (23AJH084)
Beginning on this page, you’ll find galleries with over 90 images of financial tombstones and deal toys from the biotech and life sciences space. You’ll find a number of custom designs playing off visual elements commonly associated with this space, including DNA strands, pills, lab beakers, periodic tables, as well as ones incorporating actual drug vials.
As you might also expect, you’ll see a number of deal toys involving internationally recognized firms and players. These include Takeda Pharmaceutical, Horizon Therapeutics, Gilead Sciences, Roche, Neurocrine, and Bayer. You’ll see as well tombstones commemorating transactions common to this sector involving these and other firms: joint ventures, licensing deals, and development and commercialization agreements.
But you’ll also notice a number of deals commemorated here that may involve far less familiar firms. These include the acquisition of a Dutch company focused on live-cell imaging analytics, and one of an Illinois-based gene therapy firm devoted to the treatment of a rare genetic disorder; the initial public offering of an Australian developer of radiopharmaceutical cancer therapies, and the IPO of a Norwegian biotech making use of marine compounds such as herring roe extract; early-stage funding for a Philadelphia gene engineering startup, and the IPO of an Israeli firm focused on medical applications for lipid-based compounds.
You’ll also notice in these galleries designs not related to any financial transaction. These celebrate a range of awards and employee recognition pieces honoring successful clinical trials, Food and Drug Administration (FDA) and New Drug Application (NDA) submissions, research collaborations and partnerships, and product development milestones.
"*" indicates required fields
